Drug Trial Radar · NCT02462122
Safety and Efficacy of IDP-118 in Participants With Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
215
Actual
Start
Aug 19, 2015
Primary completion
Nov 9, 2016
Study completion Nov 14, 2016
Sponsor
- Lead sponsor
- Bausch Health Americas, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Dow Pharmaceutical Sciences
- First posted
- Jun 3, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Safety and Efficacy of IDP-118 in the treatment of plaque psoriasis
Conditions
- Plaque Psoriasis
Interventions
IDP-118 LotionDrug
Lotion
IDP-118 Vehicle LotionDrug
Lotion
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Percentage of Participants With Treatment Success at Week 8Time frame: 8 weeks
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Valeant Site 5
Fremont, California
Valeant Site 2
Boynton Beach, Florida
Valeant Site 14
North Miami Beach, Florida
Valeant Site 13
Detriot, Michigan
Valeant Site 8
Warren, Michigan
Valeant Site 10
Fridley, Minnesota
Valeant Site 1
East Windsor, New Jersey
Valeant Site 4
Albuquerque, New Mexico
Valeant Site 12
New York, New York
Valeant Site 6
High Point, North Carolina
Valeant Site 3
Portland, Oregon
Valeant Site 7
Knoxville, Tennessee
Valeant Site 9
College Station, Texas
Valeant Site 15
Houston, Texas
Valeant Site 16
Houston, Texas
Valeant Site 11
Pflugerville, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.